13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Review of Onychomycosis Due to Aspergillus Species

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aspergillus spp. are emerging causative agents of non-dermatophyte mould onychomycosis (NDMO). New Aspergillus spp. have recently been described to cause nail infections. The following criteria are required to diagnose onychomycosis due to Aspergillus spp.: (1) positive direct microscopy and (2) repeated culture or molecular detection of Aspergillus spp., provided no dermatophyte was isolated. A review of 42 epidemiological studies showed that onychomycosis due to Aspergillus spp. varies between < 1 and 35% of all cases of onychomycosis in the general population and higher among diabetic populations accounting for up to 71% and the elderly; it is very uncommon among children and adolescence. Aspergillus spp. constitutes 7.7–100% of the proportion of NDMO. The toenails are involved 25 times more frequently than fingernails. A. flavus, A. terreus and A. niger are the most common aetiologic species; other rare and emerging species described include A. tubingensis, A. sydowii, A. alliaceus, A. candidus, A. versicolor, A. unguis, A. persii, A. sclerotiorum, A. uvarum, A. melleus, A. tamarii and A. nomius. The clinical presentation of onychomycosis due to Aspergillus spp. is non-specific but commonly distal–lateral pattern of onychomycosis. A negative culture with a positive KOH may point to a NDM including Aspergillus spp., as the causative agent of onychomycosis. Treatment consists of systemic therapy with terbinafine or itraconazole.

          Related collections

          Most cited references70

          • Record: found
          • Abstract: found
          • Article: found

          Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

          Non-fatal health outcomes from diseases and injuries are a crucial consideration in the promotion and monitoring of individual and population health. The Global Burden of Disease (GBD) studies done in 1990 and 2000 have been the only studies to quantify non-fatal health outcomes across an exhaustive set of disorders at the global and regional level. Neither effort quantified uncertainty in prevalence or years lived with disability (YLDs). Of the 291 diseases and injuries in the GBD cause list, 289 cause disability. For 1160 sequelae of the 289 diseases and injuries, we undertook a systematic analysis of prevalence, incidence, remission, duration, and excess mortality. Sources included published studies, case notification, population-based cancer registries, other disease registries, antenatal clinic serosurveillance, hospital discharge data, ambulatory care data, household surveys, other surveys, and cohort studies. For most sequelae, we used a Bayesian meta-regression method, DisMod-MR, designed to address key limitations in descriptive epidemiological data, including missing data, inconsistency, and large methodological variation between data sources. For some disorders, we used natural history models, geospatial models, back-calculation models (models calculating incidence from population mortality rates and case fatality), or registration completeness models (models adjusting for incomplete registration with health-system access and other covariates). Disability weights for 220 unique health states were used to capture the severity of health loss. YLDs by cause at age, sex, country, and year levels were adjusted for comorbidity with simulation methods. We included uncertainty estimates at all stages of the analysis. Global prevalence for all ages combined in 2010 across the 1160 sequelae ranged from fewer than one case per 1 million people to 350,000 cases per 1 million people. Prevalence and severity of health loss were weakly correlated (correlation coefficient -0·37). In 2010, there were 777 million YLDs from all causes, up from 583 million in 1990. The main contributors to global YLDs were mental and behavioural disorders, musculoskeletal disorders, and diabetes or endocrine diseases. The leading specific causes of YLDs were much the same in 2010 as they were in 1990: low back pain, major depressive disorder, iron-deficiency anaemia, neck pain, chronic obstructive pulmonary disease, anxiety disorders, migraine, diabetes, and falls. Age-specific prevalence of YLDs increased with age in all regions and has decreased slightly from 1990 to 2010. Regional patterns of the leading causes of YLDs were more similar compared with years of life lost due to premature mortality. Neglected tropical diseases, HIV/AIDS, tuberculosis, malaria, and anaemia were important causes of YLDs in sub-Saharan Africa. Rates of YLDs per 100,000 people have remained largely constant over time but rise steadily with age. Population growth and ageing have increased YLD numbers and crude rates over the past two decades. Prevalences of the most common causes of YLDs, such as mental and behavioural disorders and musculoskeletal disorders, have not decreased. Health systems will need to address the needs of the rising numbers of individuals with a range of disorders that largely cause disability but not mortality. Quantification of the burden of non-fatal health outcomes will be crucial to understand how well health systems are responding to these challenges. Effective and affordable strategies to deal with this rising burden are an urgent priority for health systems in most parts of the world. Bill & Melinda Gates Foundation. Copyright © 2012 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Aspergillus fumigatus—What Makes the Species a Ubiquitous Human Fungal Pathogen?

            Introduction Aspergillus fumigatus, the major cause of life threatening invasive aspergillosis (IA), is a ubiquitous saprophytic fungus to which humans are exposed daily in most parts of the world. The infection is initiated by inhalation of conidia, which are cleared quickly in a normal host but can cause invasive disease in immunocompromised individuals [1], [2]. The following features make A. fumigatus a ubiquitous pathogen: 1) survival and growth in a wide range of environmental conditions, 2) effective dispersal in the air, 3) physical characteristics that allow conidia to reach the distal airways, and 4) swift adaptability to the host environment. The biology, pathogenesis, molecular biology, and virulence factors of A. fumigatus have been exhaustively reviewed [2]–[8]. This brief article focuses on how A. fumigatus is equipped with the features necessary for a ubiquitous pathogen. Aspergillus fumigatus Is Equipped to Survive and Propagate Successfully under a Wide Range of Environmental Conditions In most parts of the world, Aspergillus fumigatus can be isolated from a wide variety of substrates throughout the year. Although A. fumigatus grows optimally at 37°C and a pH 3.7 to 7.6, it can be isolated wherever decaying vegetation and soil reach temperatures range between 12° and 65°C [9] and the pH ranges between 2.1–8.8 [10]. A. fumigatus was found to be the dominant fungus in garden and greenhouse soil that comprised 35 to 70 percent of the total numbers of colony-forming fungi [10]. As an efficient recycler in nature, A. fumigatus possesses a versatile metabolism that meets its nutritional requirements under different environmental conditions [11]. The presence of numerous glycosylhydrolases [6] and a group of extracellular proteinases in the A. fumigatus genome attest to the ability of the fungus to grow by degradation of polysaccharides from plant cell walls and acquire nitrogen sources made available by degradation of proteinacious substrates [8]. Self-heating compost heaps are major environmental sources of A. fumigatus due to its pronounced thermotolerance. One study found 100,000 colony-forming units (cfu)/gram/dry weight of compost [12], and compost piles of chipped leaves and branches may yield massive and almost pure cultures of A. fumigatus [1]. The thermotolerance of A. fumigatus is even more remarkable in the ascospores, the propagules produced in the sexual cycle. The ascospores of A. fumigatus (Figure 1A) are protected by an extraordinarily thick wall (Figure 1B) compared to those of other aspergilli such as A. nidulans [13]. The ascospores of A. fumigatus germinate after heating at 70°C for 30 min [14] (Figure 1C) and should survive at core temperatures of the compost pile that can reach ≥70°C [2]. 10.1371/journal.ppat.1003743.g001 Figure 1 Aspergillus fumigatus ascospores. A) SEM image of an ascospore produced by mating between two compatible strains. Courtesy of Bryan Hansen. B) TEM image of an ascospore cross-section showing an unusually thick wall (white bar) composed of an electron-dense inner wall covered by a thick outer wall. Courtesy of Mones Abu-Asab. C) DIC image of germinating ascospores (white arrows) and dead conidia (black arrow) after 30 min incubation at 70°C. Although A. fumigatus fails to grow at temperatures below 12°C, its conidia can tolerate stresses imposed by freezing for prolonged periods. Depending on the strain, conidia can survive in liquid nitrogen for up to 18 years [9]. Although a few genes associated with fungal growth at ≥48°C have been characterized, the genetic systems involved in survival and growth under extreme temperatures remain unidentified [15]. A. fumigatus conidia can also tolerate dehydration for prolonged periods, surviving for more than 60 years when lyophilized, and the conidia that had been maintained in anhydrous silica gel survived for more than 25 years (unpublished data). The wide distribution of A. fumigatus in nature may also be due to the presence of successful defense systems such as the production of potent secondary metabolites and efflux pumps. The A. fumigatus genome contains 22 secondary metabolism gene clusters [11] and 16 different secondary metabolites have been identified [16], including gliotoxin, a broad range antimicrobial [17]. A. fumigatus possesses a higher number of ABC transporters than its close genetic relative, Aspergillus fischerianus [15]. The A. fumigatus genome is also rich in specific enzymes such as catalases, superoxide dismutases, and glutathione transferases for the detoxification of reactive oxygen species (ROS) [8], [18]. All these features equip A. fumigatus to survive and propagate in conditions that are detrimental to a broad range of other environmental organisms. Aspergillus fumigatus Conidia Are Dispersed More Efficiently in the Air Than Those of Most Other Molds Aspergillus fumigatus conidia accumulate 1,8-dihydroxynaphthalene melanin in their cell wall, have a blue-green color [19], [20], and are notorious for their high dispersibility. The slightest air current can cause conidia to disperse due to their remarkable hydrophobicity, and these airborne conidia are protected from ultraviolet irradiation due to the melanin in their cell wall [20]. One study has estimated the emission rate of A. fumigatus conidia from an undisturbed compost pile to be 8–11×103 cfu/m2/s at the mean wind speed of 1 m/s [21], which indicates how efficiently conidia are dispersed with the slightest agitation. Figure 2A shows an aerosol cloud over a disturbed compost pile. A majority of the microbial growth on a plate of agar medium briefly exposed to the air at the site was that of A. fumigatus (Figure 2B). Although all fungal spores produced on aerial hyphae or conidiophores are hydrophobic, the degree varies from mild to highly hydrophobic [22] which impacts the efficiency of spore dispersibility. A. fumigatus conidia are considerably more hydrophobic than those of other aspergilli such as A. nidulans. This requires more caution in the handling of A. fumigatus cultures than other fungi to prevent contamination of surrounding areas in the laboratory (Figure 2C, D). Conidial hydrophobicity is conferred by the surface rodlet layer encoded by the rodA gene [23]. In addition to dispersal of airborne conidia, conidia imbedded in soil may also be effectively transported from one place to another by swarming soil bacteria such as Paenibacillus vortex. P. vortex facilitates the dispersal of A. fumigatus more efficiently than other fungal species that have similarly sized conidia such as Penicillium expansum or P. citrinum [24]. Conidial surface proteins are crucial for the passive dispersal of A. fumigatus by the bacteria since proteinase K treatment of conidia abolished the conidia-bacterial interaction. Undoubtedly, A. fumigatus conidia are also being passively dispersed via rodents, insects, and worms but the impact of A. fumigatus spread by these means has not been studied. 10.1371/journal.ppat.1003743.g002 Figure 2 Dispersibility of A. fumigatus conidia. A) A cloud of aerosol released in the air after turning of a compost pile located in Maryland, USA. B) A malt extract agar plate exposed to the air for a minute at the site and incubated for a few days at 37°C grew predominantly A. fumigatus colonies (both pictures were taken by the late Dr. Chester Emmons). C) Eight small sterile agar plates of Aspergillus minimal medium were placed around a seven-day-old culture of A. fumigatus strain B-5233 (center) in a class 2 biosafety cabinet. In the absence of air flow the lids of all the plates were removed for 24 h. The small plates were then incubated for three days at 37°C. D) The same procedure as in C except that the small plates were exposed to the culture of a ten-day-old A. nidulans strain RYC13B (center). A. fumigatus conidia dispersed to the surrounding small agar plates while none was evident for the A. nidulans strain. Physical Characteristics of Conidia That Contribute to Respiratory Tract Disease Fungal spores account for a significant proportion of the aerosol particle mass that the human respiratory system is exposed to daily. Airborne fungal spores exist in various sizes and any spore with a size of ≥5.0 µm (diameter) is too large to reach the lower airways [25] where systemic infection is primarily initiated. A. fumigatus conidia are globose to subglobose with a size (2.0–3.0 µm in diameter with extremes up to 3.5 µm) adequate to bypass mucociliary clearance and reach the lower airways. The average adult inhales more than 100 A. fumigatus conidia daily since the conidial concentration in the air indoors or outdoors is estimated to be 1–100 conidia/m3 [4]. Conidial size does not change significantly with increased relative humidity from 30% to 90% [26], and so airborne conidia maintain an optimum size for reaching the lower airways regardless of the relative humidity. Melanin in the conidial wall offers protection from ROS while also enabling resistance to lysis by host cells [4]. A. fumigatus conidial surface contains more exposed negatively charged sialic acid residues than other Aspergillus species and sialic acid partly mediates binding to basal lamina proteins of the host [27]. A. fumigatus conidia, therefore, may adhere to the epithelium of airways and alveoli more effectively than other fungal species with similarly sized airborne spores. Aspergillus fumigatus Conidia Germinate and Adapt Readily to the Immunocompromised Host Environment Aspergillus fumigatus conidia that reach the alveoli are unable to withstand the immune assault mounted by normal hosts because the fungus lacks specialized virulence factors [6]. However, patients who are undergoing organ transplantation, cancer chemotherapy, or have chronic granulomatous disease (CGD) as an underlying condition are highly susceptible to infection by the fungus because the inhaled conidia can efficiently adapt their physiology to the altered host environment. A review of 146 autopsies at the National Institutes of Health over a 22-year period showed no firm link between hospital exposure and an increased incidence of invasive aspergillosis. There was, however, a clear link between cancer chemotherapy regimens and increased incidence [28]. This indicates that adaptability of A. fumigatus to the human environment, though successful, is secondary to the host immune status. Inhaled conidia readily germinate at the mammalian body temperature since 37°C is the optimum temperature for both germination and growth. Conidia shed the hydrophobin layer and swell in 4 h to germinate into short hyphae by 6–8 h at 37°C in vitro as well as in immunocompromised mammalian tissue [29]. During this early growth period, A. fumigatus responds to the stress imposed by the host environment by utilizing a highly coordinated gene expression program that enables adaptation to iron limitation, nitrogen and glucose deprivation, alkaline stress, and other unfavorable conditions [29]. One of the features during early infection in mice is the activation of gliotoxin biosynthesis [29]. Since gliotoxin is immunosuppressive and cytocidal [17], it can be speculated that the fungus benefits from nutrients released by the gliotoxin-destroyed host cells. Presence of the toxin in sera of patients infected with A. fumigatus suggests its involvement in the adaptation to the host environment [17]. How efficiently A. fumigatus cells can sense and respond to the host environment has been shown by clear differences in transcriptional profiles between conidia exposed to the neutrophils of normal host compared to those from patients with CGD, which are defective in ROS production [30]. All these features indicate that, being equipped to grow in a wide range of unfavorable conditions in nature, A. fumigatus finds the immunocompromised host environment just another adverse condition to which it can successfully adapt. Concluding Remarks Among the over 200 species of Aspergillus, A. fumigatus is the best at meeting the four features discussed in this review. Since innate immunity protects against Aspergillus, the reason for the wide spread of IA caused by A. fumigatus is due to the global distribution of both the fungus and an increase in susceptible hosts. However, only a portion of the high-risk population, such as those with stem cell transplantation or CGD, develop IA despite daily exposure to the fungus. This suggests that a genetic risk associated with aspergillosis may exist in IA patients in addition to their underlying immunosuppressive condition. Although several studies on the role of immune-related gene SNPs of both donors and recipients of stem cell transplant have been conducted, the genetic factors that confer increased susceptibility to IA have yet to be validated. In light of the high fatality rate of IA, identification of such factors would improve prophylactic measures against not only IA but invasive infection by other mold species.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              British Association of Dermatologists' guidelines for the management of onychomycosis 2014.

                Bookmark

                Author and article information

                Contributors
                +44161 291 5811 , ddenning@manchester.ac.uk
                Journal
                Mycopathologia
                Mycopathologia
                Mycopathologia
                Springer Netherlands (Dordrecht )
                0301-486X
                1573-0832
                16 November 2017
                16 November 2017
                2018
                : 183
                : 3
                : 485-493
                Affiliations
                [1 ]ISNI 0000000121662407, GRID grid.5379.8, The National Aspergillosis Centre, Education and Research Centre, Wythenshawe Hospital, , Manchester University NHS Foundation Trust, ; Southmoor Road, Manchester, M23 9LT UK
                [2 ]ISNI 0000 0000 9650 2179, GRID grid.11159.3d, Skin Study Group, Institute of Herbal Medicine, National Institutes of Health, University of the Philippines - Manila, ; Manila, Philippines
                [3 ]ISNI 0000000121662407, GRID grid.5379.8, NHS Mycology Reference Centre, Wythenshawe Hospital, , Manchester University NHS Foundation Trust, ; Southmoor Road, Manchester, M23 9LT UK
                [4 ]ISNI 0000000121662407, GRID grid.5379.8, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, , The University of Manchester, ; Oxford Road, Manchester, M13 9PL UK
                Author information
                http://orcid.org/0000-0001-5626-2251
                Article
                222
                10.1007/s11046-017-0222-9
                5958150
                29147866
                b72766d9-33b1-49d8-981f-919e2194d7d5
                © The Author(s) 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 21 August 2017
                : 2 November 2017
                Funding
                Funded by: Global Action Fund for Fungal Infections
                Award ID: N/A
                Award Recipient :
                Categories
                Review Paper
                Custom metadata
                © Springer Science+Business Media B.V., part of Springer Nature 2018

                Infectious disease & Microbiology
                aspergillus,onychomycosis,clinical features,epidemiology,mycology

                Comments

                Comment on this article